CVS halts sale of Zantac products

CVS Pharmacy has suspended the sale of Zantac and other ranitidine products at its drugstores after the FDA flagged a possible human carcinogen in the popular heartburn drugs.

In a Sept. 28 statement, CVS said it made the decision "out of an abundance of caution."

The decision to freeze sales of the drug comes as the FDA is evaluating whether small amounts of the carcinogen, N-nitrosodimethylamine, pose a risk to patients.

To date, no recall has been issued on Sanofi's brand-name drug Zantac.

Customers who bought Zantac at CVS can return it for a refund.

Read the full article here.

More articles on pharmacy:
World Pharmacist Day promotes use of safe and effective medicines
USP delays release of updated compounding standards
Americans pay up to 67 times more for drugs than other countries.

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Content

Featured Webinars

Featured Whitepapers